Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
Description:
In today’s episode, the discussion features Aditya Bardia, MD, MPH, FASCO. Dr Bardia is a professor in the Department of Medicine in the Division of Hematology/Oncology, the director of Translational Research Integration, and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California.In the exclusive interview, Dr Bardia discussed the rationale and design of the phase 3 ELEGANT study (NCT06492616), which is evaluating elacestrant (Orserdu) compared with standard endocrine therapy in patients with estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recu...